Mark A Socinski Selected Research

Paclitaxel (Taxol)

1/2022	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
1/2022	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
1/2020	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
1/2020	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
1/2019	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
1/2018	nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
1/2016	Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
5/2015	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
3/2015	Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
2/2015	Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Socinski Research Topics

Disease

151	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2022 - 03/2002
70	Neoplasms (Cancer) 02/2022 - 10/2002
31	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2004
27	Disease Progression 01/2021 - 09/2002
23	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017 - 04/2003
19	Neutropenia 01/2021 - 11/2002
10	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2006
10	Thrombocytopenia (Thrombopenia) 01/2018 - 10/2006
9	Adenocarcinoma of Lung 01/2021 - 11/2006
9	Carcinoma (Carcinomatosis) 01/2018 - 07/2002
8	Fatigue 01/2018 - 06/2005
8	Adenocarcinoma 01/2018 - 08/2009
8	Leukemia 01/2017 - 04/2003
7	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2007
7	Anemia 01/2021 - 10/2009
7	Febrile Neutropenia 01/2020 - 04/2008
7	Exanthema (Rash) 10/2017 - 04/2005
6	Pneumonia (Pneumonitis) 06/2020 - 07/2002
5	Esophagitis 05/2013 - 10/2002
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 08/2003
4	Hypertension (High Blood Pressure) 01/2020 - 04/2008
4	Hemorrhage 01/2018 - 04/2008
3	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 04/2007
3	Leukopenia 01/2018 - 10/2009
3	Diarrhea 10/2017 - 11/2002
3	Nausea 10/2017 - 04/2005
3	Infections 01/2017 - 07/2002
3	Mucositis 01/2017 - 04/2005
3	Alopecia (Baldness) 12/2013 - 06/2008
2	Cough 01/2018 - 07/2002
2	Malignant Mesothelioma 11/2017 - 04/2005
2	Acne Vulgaris 07/2015 - 11/2008
2	Melanoma (Melanoma, Malignant) 02/2014 - 05/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2012 - 10/2010

Drug/Important Bio-Agent (IBA)

55	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 09/2002
44	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 07/2002
28	Bevacizumab (Avastin)FDA Link 02/2022 - 09/2007
24	PlatinumIBA 01/2022 - 09/2002
24	Pemetrexed (MTA)FDA Link 01/2022 - 04/2005
22	Gemcitabine FDA Link 10/2019 - 07/2002
15	ErbB Receptors (EGF Receptor)IBA 07/2022 - 08/2007
14	Docetaxel (Taxotere)FDA Link 01/2020 - 09/2002
12	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 11/2002
11	Tyrosine Kinase InhibitorsIBA 07/2022 - 05/2007
11	130-nm albumin-bound paclitaxelIBA 01/2021 - 05/2008
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2009
10	Pharmaceutical PreparationsIBA 01/2017 - 07/2002
9	Monoclonal AntibodiesIBA 02/2022 - 04/2008
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2010
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 02/2008
7	atezolizumabIBA 01/2022 - 06/2018
7	necitumumabIBA 10/2019 - 03/2015
7	Gefitinib (Iressa)FDA Link 01/2017 - 06/2006
7	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 01/2005
7	SolventsIBA 01/2016 - 10/2007
6	Immune Checkpoint InhibitorsIBA 01/2022 - 02/2014
6	B7-H1 AntigenIBA 01/2021 - 10/2015
6	Sunitinib (Sutent)FDA Link 01/2017 - 02/2008
6	Irinotecan (Camptosar)FDA LinkGeneric 03/2008 - 10/2002
5	Albumin-Bound Paclitaxel FDA Link 01/2021 - 10/2007
5	CrizotinibIBA 10/2020 - 01/2011
5	AntibodiesIBA 01/2018 - 08/2007
4	Anaplastic Lymphoma KinaseIBA 10/2020 - 12/2014
4	NivolumabIBA 01/2017 - 01/2015
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2015 - 05/2007
4	taxaneIBA 01/2014 - 07/2002
4	Vinorelbine (Navelbine)FDA LinkGeneric 07/2008 - 06/2004
3	nintedanibIBA 01/2018 - 12/2011
3	alectinibIBA 01/2018 - 02/2016
3	LigandsIBA 10/2015 - 03/2010
3	Biological ProductsIBA 01/2015 - 11/2004
3	Proteins (Proteins, Gene)FDA Link 09/2014 - 01/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 12/2011
2	AlbuminsIBA 01/2021 - 10/2012
2	Biosimilar PharmaceuticalsIBA 01/2021 - 01/2015
2	RamucirumabIBA 01/2020 - 01/2018
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2017 - 10/2015
2	STA 9090IBA 05/2015 - 06/2013
2	Topotecan (Hycamtin)FDA LinkGeneric 12/2014 - 01/2005
2	pazopanib FDA Link 11/2014 - 12/2011
2	EnzymesIBA 09/2014 - 04/2005
2	AntigensIBA 02/2014 - 01/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2013 - 08/2009
2	Hematoxylin (Haematoxylon)IBA 01/2013 - 08/2009
2	Taxoids (Taxanes)IBA 10/2012 - 07/2002
2	Sorafenib (BAY 43-9006)FDA Link 12/2011 - 02/2011
2	Platelet-Derived Growth FactorIBA 12/2011 - 02/2008
2	Cetuximab (Erbitux)FDA Link 01/2011 - 02/2010
2	matuzumabIBA 12/2010 - 08/2007

Therapy/Procedure

84	Therapeutics 01/2022 - 03/2002
63	Drug Therapy (Chemotherapy) 01/2022 - 03/2002
23	Radiotherapy 11/2017 - 10/2002
10	Combined Modality Therapy 03/2008 - 10/2004
8	Chemoradiotherapy 11/2021 - 07/2005
7	Immunotherapy 01/2020 - 01/2014
5	Conformal Radiotherapy 11/2011 - 10/2002
4	Induction Chemotherapy 09/2017 - 03/2008
3	Duration of Therapy 07/2009 - 03/2002
2	Aftercare (After-Treatment) 01/2018 - 05/2017
2	Intravenous Infusions 06/2013 - 02/2008